Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.

@article{Baares1999CarvedilolAN,
  title={Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.},
  author={Rafael Ba{\~n}ares and Eduardo Moitinho and Bel{\'e}n Piqueras and Marta Zubiaur Gonz{\'a}lez y Melania del Riego Casado and Juan Carlos Garc{\'i}a-Pag{\'a}n and Alejandro De Diego and J Bosch},
  journal={Hepatology},
  year={1999},
  volume={30 1},
  pages={
          79-83
        }
}
Only some patients show a substantial hepatic venous pressure gradient (HVPG) reduction after propranolol, which makes it desirable to investigate drugs with greater portal hypotensive effect. The aim of this study was to investigate whether carvedilol, a nonselective beta-blocker with anti-alpha1-adrenergic activity, may cause a greater HVPG reduction than propranolol. Thirty-five cirrhotic patients had hemodynamic measurements before and after the random administration of carvedilol (n = 14… CONTINUE READING
Highly Cited
This paper has 27 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations